[go: up one dir, main page]

CN114008035A - 一种shp2磷酸酶变构抑制剂 - Google Patents

一种shp2磷酸酶变构抑制剂 Download PDF

Info

Publication number
CN114008035A
CN114008035A CN202080043751.5A CN202080043751A CN114008035A CN 114008035 A CN114008035 A CN 114008035A CN 202080043751 A CN202080043751 A CN 202080043751A CN 114008035 A CN114008035 A CN 114008035A
Authority
CN
China
Prior art keywords
allosteric inhibitor
shp2 phosphatase
inhibitor
shp2
phosphatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080043751.5A
Other languages
English (en)
Inventor
王虎庭
张磊
王永钢
樊立新
刘磊
魏栋
王静
王娇娇
默董亮
金明吉
彭勇
孟坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Shengnuoji Pharmaceutical Technology Co Ltd
Original Assignee
Beijing Shengnuoji Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Shengnuoji Pharmaceutical Technology Co Ltd filed Critical Beijing Shengnuoji Pharmaceutical Technology Co Ltd
Priority to CN202310907352.4A priority Critical patent/CN117209471A/zh
Priority to CN202310905773.3A priority patent/CN117209470A/zh
Priority to CN202310903760.2A priority patent/CN117209475A/zh
Publication of CN114008035A publication Critical patent/CN114008035A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种SHP2磷酸酶变构抑制剂，以及含有该抑制剂的药物，所述的SHP2磷酸酶变构抑制剂具有如下式(I)所示的结构，所述的SHP2磷酸酶变构抑制剂的光学异构体化合物或其药学上可接受的盐在制备用于治疗肿瘤疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202080043751.5A 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂 Pending CN114008035A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202310907352.4A CN117209471A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310905773.3A CN117209470A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310903760.2A CN117209475A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019105151960 2019-06-14
CN201910515196 2019-06-14
CN2019110688218 2019-11-04
CN201911068821 2019-11-04
CN202010056703 2020-01-17
CN2020100567031 2020-01-17
CN202010517372 2020-06-09
CN2020105173727 2020-06-09
PCT/CN2020/095795 WO2020249079A1 (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202310905773.3A Division CN117209470A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310903760.2A Division CN117209475A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310907352.4A Division CN117209471A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂

Publications (1)

Publication Number Publication Date
CN114008035A true CN114008035A (zh) 2022-02-01

Family

ID=73780909

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202080043751.5A Pending CN114008035A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310905773.3A Pending CN117209470A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310903760.2A Pending CN117209475A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310907352.4A Pending CN117209471A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310905773.3A Pending CN117209470A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310903760.2A Pending CN117209475A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂
CN202310907352.4A Pending CN117209471A (zh) 2019-06-14 2020-06-12 一种shp2磷酸酶变构抑制剂

Country Status (7)

Country Link
US (1) US12209074B2 (zh)
EP (1) EP3984999A4 (zh)
JP (1) JP7335003B2 (zh)
KR (1) KR102727832B1 (zh)
CN (4) CN114008035A (zh)
TW (1) TW202112761A (zh)
WO (1) WO2020249079A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
JP2023530351A (ja) 2020-06-18 2023-07-14 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
KR20230167347A (ko) * 2021-02-05 2023-12-08 허치메드 리미티드 트리사이클릭 화합물 및 이의 용도
JP2024517847A (ja) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
WO2022242767A1 (zh) * 2021-05-21 2022-11-24 石药集团中奇制药技术（石家庄）有限公司 螺环类化合物及其用途
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202446388A (zh) 2023-04-14 2024-12-01 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
WO2018172984A1 (en) * 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2019051084A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
TW202003471A (zh) 2018-03-21 2020-01-16 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
WO2018172984A1 (en) * 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2019051084A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER

Also Published As

Publication number Publication date
JP7335003B2 (ja) 2023-08-29
EP3984999A4 (en) 2023-11-22
KR20220061087A (ko) 2022-05-12
JP2022535998A (ja) 2022-08-10
EP3984999A1 (en) 2022-04-20
TW202112761A (zh) 2021-04-01
US20220388977A1 (en) 2022-12-08
CN117209475A (zh) 2023-12-12
KR102727832B1 (ko) 2024-11-08
CN117209470A (zh) 2023-12-12
CN117209471A (zh) 2023-12-12
US12209074B2 (en) 2025-01-28
WO2020249079A1 (zh) 2020-12-17

Similar Documents

Publication Publication Date Title
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
CN113853373A (zh) 取代的杂环并环类化合物，其制法与医药上的用途
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
CN114728974A (zh) 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN114829364A (zh) 抑制并诱导降解egfr激酶的化合物
CN114269746A (zh) 一种螺芳环化合物、其制备及应用
IL307260A (en) Method for treating cancer
CN114466853A (zh) 抗癌化合物及其医药用途
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2016536286A5 (zh)
JP2020097577A5 (zh)
CN111065639A (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN111699174A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN111788205A (zh) 吡唑并嘧啶衍生物及其用途
CN115397822A (zh) Cbp/ep300抑制剂及其用途
CN114466846A (zh) 作为prmt5抑制剂的取代三环类化合物及其应用
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
CN114761411A (zh) 作为erk抑制剂的螺环类化合物及其应用
JP2015521156A5 (zh)
CN114423760A (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
MY199779A (en) Pyrrolopyrimidine compound and use thereof
JP2020529995A5 (zh)
JP2015516419A5 (zh)
CN114364685A (zh) 含氮杂环类化合物，及其制备方法、药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220201

RJ01 Rejection of invention patent application after publication